Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more
Relmada Therapeutics Inc (RLMD) - Net Assets
Latest net assets as of September 2025: $9.47 Million USD
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has net assets worth $9.47 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.88 Million) and total liabilities ($5.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.47 Million |
| % of Total Assets | 63.63% |
| Annual Growth Rate | 95.55% |
| 5-Year Change | -66.36% |
| 10-Year Change | 303.2% |
| Growth Volatility | 2942.03 |
Relmada Therapeutics Inc - Net Assets Trend (2012–2024)
This chart illustrates how Relmada Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Relmada Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Relmada Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $35.52 Million | -58.38% |
| 2023-12-31 | $85.36 Million | -39.22% |
| 2022-12-31 | $140.44 Million | -32.57% |
| 2021-12-31 | $208.26 Million | +97.25% |
| 2020-12-31 | $105.58 Million | -8.73% |
| 2019-12-31 | $115.68 Million | +2198.25% |
| 2018-12-31 | $-5.51 Million | -477.53% |
| 2017-12-31 | $1.46 Million | -79.26% |
| 2016-12-31 | $7.04 Million | -20.06% |
| 2015-12-31 | $8.81 Million | 0.00% |
| 2014-12-31 | $8.81 Million | +894.43% |
| 2014-06-30 | $-1.11 Million | 0.00% |
| 2013-12-31 | $-1.11 Million | -9863.70% |
| 2012-12-31 | $11.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Relmada Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64086989300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.17K | 0.08% |
| Other Components | $676.37 Million | 1904.10% |
| Total Equity | $35.52 Million | 100.00% |
Relmada Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Relmada Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chongqing Water Group Co Ltd
SHG:601158
|
$330.74 Million |
|
Hollyland China Electronics Technology Corp Ltd
SHE:002729
|
$330.83 Million |
|
Danhua Chemical Technology Co Ltd A
SHG:600844
|
$330.83 Million |
|
EPIC Suisse AG
SW:EPIC
|
$331.03 Million |
|
Galatasaray Sportif Sinai ve Ticari Yatirimlar AS
IS:GSRAY
|
$330.71 Million |
|
Shanghai Kai Kai Industry Co Ltd A
SHG:600272
|
$330.69 Million |
|
Dave & Buster’s Entertainment
NASDAQ:PLAY
|
$330.63 Million |
|
Ls Cable & System Asia Ltd
KO:229640
|
$330.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relmada Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 85,357,242 to 35,521,961, a change of -49,835,281 (-58.4%).
- Net loss of 79,979,354 reduced equity.
- New share issuances of 246,747 increased equity.
- Other factors increased equity by 29,897,326.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-79.98 Million | -225.15% |
| Share Issuances | $246.75K | +0.69% |
| Other Changes | $29.90 Million | +84.17% |
| Total Change | $- | -58.38% |
Book Value vs Market Value Analysis
This analysis compares Relmada Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1788.34x to 5.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $6.45 | x |
| 2013-12-31 | $-2.27 | $6.45 | x |
| 2014-06-30 | $-0.92 | $6.45 | x |
| 2014-12-31 | $3.54 | $6.45 | x |
| 2015-12-31 | $3.55 | $6.45 | x |
| 2016-12-31 | $2.43 | $6.45 | x |
| 2017-12-31 | $0.48 | $6.45 | x |
| 2018-12-31 | $-1.76 | $6.45 | x |
| 2019-12-31 | $12.53 | $6.45 | x |
| 2020-12-31 | $6.77 | $6.45 | x |
| 2021-12-31 | $11.87 | $6.45 | x |
| 2022-12-31 | $4.74 | $6.45 | x |
| 2023-12-31 | $2.84 | $6.45 | x |
| 2024-12-31 | $1.18 | $6.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relmada Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -225.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-225.15%) is below the historical average (-125.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -106.11% | -151.77% | 0.43x | 1.62x | $-13.19K |
| 2013 | 0.00% | -877.66% | 0.00x | 0.00x | $5.48 Million |
| 2014 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2015 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2016 | -42.24% | 0.00% | 0.00x | 1.45x | $-3.68 Million |
| 2017 | -430.53% | 0.00% | 0.00x | 1.94x | $-6.43 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.41 Million |
| 2019 | -12.97% | 0.00% | 0.00x | 1.01x | $-26.57 Million |
| 2020 | -56.31% | 0.00% | 0.00x | 1.12x | $-70.01 Million |
| 2021 | -60.38% | 0.00% | 0.00x | 1.07x | $-146.58 Million |
| 2022 | -111.83% | 0.00% | 0.00x | 1.09x | $-171.09 Million |
| 2023 | -115.74% | 0.00% | 0.00x | 1.14x | $-107.33 Million |
| 2024 | -225.15% | 0.00% | 0.00x | 1.29x | $-83.53 Million |
Industry Comparison
This section compares Relmada Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relmada Therapeutics Inc (RLMD) | $9.47 Million | -106.11% | 0.57x | $330.73 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |